نتائج البحث - "PD‐1/PD‐L1 inhibitor"

1

Clinical observation of the efficacy of PD‐1/PD‐L1 inhibitors in the treatment of patients with advanced solid tumors

المؤلفون: Hongchao Zhen, Yuhan Wei, Yuting Lu, Xiaoyue Jiang, Jiangtao Jin, Miao Wang, Qin Li

المصدر: Immunity, Inflammation and Disease, Vol 9, Iss 4, Pp 1584-1595 (2021)
Immunity, Inflammation and Disease

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ac27fe9d73aa684f34a349e058effc4Test
https://doaj.org/article/7e67fd62bbea405ca3ca1c424f2c1796Test

2

Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival

المؤلفون: Hai-Yang Chen, Yongchen Wang, Ximin Pan, Qinmei Xu, Changguan Tang, Peiyi Xie, Xiaochun Meng, Olivier Gevaert, Kaikai Wei, Hong Zheng

المصدر: BMC Cancer
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)

مصطلحات موضوعية: Adult, Male, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, medicine.disease_cause, DNA Mismatch Repair, Gastroenterology, Pseudoprogression, Surgical oncology, Internal medicine, Genetics, medicine, Advanced gastrointestinal malignancies, Humans, Immune Checkpoint Inhibitors, RC254-282, Response Evaluation Criteria in Solid Tumors, Gastrointestinal Neoplasms, Retrospective Studies, Analysis of Variance, Univariate analysis, business.industry, Research, Age Factors, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Cancer, PD-1/PD-L1 inhibitor, Retrospective cohort study, Immunotherapy, Middle Aged, medicine.disease, Tumor Burden, Genes, ras, Treatment Outcome, Oncology, Female, KRAS, Tumor response, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc941f217af0fae0b3448d00c81044d3Test
https://doi.org/10.1186/s12885-021-08944-9Test

3

Effects of concomitant proton pump inhibitor use on immune checkpoint inhibitor efficacy among patients with advanced cancer

المؤلفون: Yan Ling, Bin Shi, Bao-Dong Qin, Ying Wu, Ke Liu, Jian Wang, Yuan-Sheng Zang, Xin-Cheng Zhou, Xiao-Dong Jiao

المصدر: Oncoimmunology
article-version (VoR) Version of Record
OncoImmunology, Vol 10, Iss 1 (2021)

مصطلحات موضوعية: Oncology, medicine.medical_specialty, Lung Neoplasms, medicine.drug_class, proton pump inhibitor, medicine.medical_treatment, Immune checkpoint inhibitors, overall survival, Immunology, Proton-pump inhibitor, Internal medicine, Carcinoma, Non-Small-Cell Lung, medicine, Immunology and Allergy, Humans, In patient, CTLA-4 inhibitor, Progression-free survival, RC254-282, Original Research, business.industry, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, PD-1/PD-L1 inhibitor, Proton Pump Inhibitors, Immunotherapy, RC581-607, Advanced cancer, Concomitant, Electronic database, immunotherapy, Immunologic diseases. Allergy, business, progression-free survival, Research Article

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b926027598205cd0cc6e9011d88d008cTest
http://europepmc.org/articles/PMC8296970Test

4

Optimizing the Treatment Schedule of Radiotherapy Combined With Anti-PD-1/PD-L1 Immunotherapy in Metastatic Cancers

المؤلفون: Yuehong Kong, Yifu Ma, Xiangrong Zhao, Jie Pan, Zhi Xu, Liyuan Zhang

المصدر: Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96957ac41e5388d48592392628fb5de2Test
https://doi.org/10.3389/fonc.2021.638873Test

5

Japan Society of Clinical Oncology provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors, cooperated by Japanese Society of Medical Oncology, First Edition

المؤلفون: Masafumi Ikeda, Yasuhiro Kodera, Eishi Baba, Osamu Maeda, Yutaka Fujiwara, Hiroshi Nishihara, Katsuya Tsuchihara, Takayuki Yoshino, Tadao Takano, Yasushi Yatabe, Saori Mishima, Kiwamu Akagi, Akira Hirasawa, Hiroya Taniguchi, Kei Muro, Hiroyki Nishiyama

المصدر: International Journal of Clinical Oncology

مصطلحات موضوعية: 0301 basic medicine, Oncology, medicine.medical_specialty, medicine.medical_treatment, Programmed Cell Death 1 Receptor, Medical Oncology, DNA Mismatch Repair, B7-H1 Antigen, Special Article, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Japan, Surgical oncology, Neoplasms, Internal medicine, dMMR, medicine, Humans, In patient, Molecular Targeted Therapy, Provisional clinical opinion, Mismatch repair-deficient advanced solid tumor, Clinical Oncology, business.industry, MSI-H, PD-1/PD-L1 inhibitor, Hematology, General Medicine, Immunotherapy, Guideline, medicine.disease, Colorectal Neoplasms, Hereditary Nonpolyposis, Primary tumor, Clinical trial, 030104 developmental biology, 030220 oncology & carcinogenesis, Surgery, DNA mismatch repair, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca6f0c8876e4e6cbab212125113ac87fTest
https://doi.org/10.1007/s10147-019-01498-8Test

6

Molecular characterization of clinical responses to PD‐1/PD‐L1 inhibitors in non‐small cell lung cancer: Predictive value of multidimensional immunomarker detection for the efficacy of PD‐1 inhibitors in Chinese patients

المؤلفون: Kai Wang, Xiangdong Zhou, Qi Wang, Xiaoxia Cui, Xiaoyu Zhang, Chunxue Bai, Li Zhang, Jian Zhang, Jianping Zhao, Peng Song, Xiaoju Zhang, Faguang Jin, Yao Yu, Li Bai, Xiaoli Zhu, Yanbin Zhou, Chengzhi Zhou

المصدر: Thoracic Cancer

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, Lung Neoplasms, Adolescent, medicine.medical_treatment, Programmed Cell Death 1 Receptor, Pembrolizumab, NSCLC, Multi‐omics, B7-H1 Antigen, Young Adult, Study Protocol, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, PD‐1/PD‐L1 inhibitor, Carcinoma, Non-Small-Cell Lung, PD-L1, Internal medicine, Biomarkers, Tumor, medicine, Humans, Molecular Targeted Therapy, predictive biomarker, Lung cancer, Aged, Response rate (survey), biology, business.industry, General Medicine, Immunotherapy, Middle Aged, medicine.disease, Clinical trial, Treatment Outcome, 030104 developmental biology, 030220 oncology & carcinogenesis, biology.protein, Immunohistochemistry, Female, Nivolumab, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::adb9f8018da18f4739ee639337e1c7efTest
https://doi.org/10.1111/1759-7714.13078Test

7

Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort

المؤلفون: Mehmet Asim Bilen, Jodi Lyn Layton, Whitley Hatton, Hamid Emamekhoo, Vadim S. Koshkin, Patrick Cotogno, Arpita Desai, Ellen Jaeger, Oliver Sartor, Charlotte Manogue, Pedro C. Barata, Brian E. Lewis, Arnab Basu, Deepak Kilari, Malcolm Light

المصدر: Frontiers in Oncology, Vol 10 (2020)
Frontiers in Oncology

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72baaf9b29a04077ea16b6e461cf8366Test
https://www.frontiersin.org/articles/10.3389/fonc.2020.581189/fullTest

8

Efficacy and safety of PD-1/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small cell lung cancer: A systematic review and meta-analysis

المؤلفون: Shuang Li, Ying Cheng, Shuang Zhang

المصدر: Thoracic Cancer

مصطلحات موضوعية: 0301 basic medicine, Pulmonary and Respiratory Medicine, Oncology, Male, medicine.medical_specialty, Lung Neoplasms, medicine.medical_treatment, Programmed Cell Death 1 Receptor, immune checkpoint inhibitor, 03 medical and health sciences, 0302 clinical medicine, PD‐1/PD‐L1 inhibitor, Internal medicine, medicine, Biomarkers, Tumor, Humans, Adverse effect, Neoplasm Staging, Chemotherapy, business.industry, Incidence (epidemiology), Hazard ratio, General Medicine, Immunotherapy, Original Articles, Small Cell Lung Carcinoma, Progression-Free Survival, Clinical trial, 030104 developmental biology, First‐line treatment, meta‐analysis, 030220 oncology & carcinogenesis, Meta-analysis, Female, Original Article, small cell lung cancer, business, PD-L1 inhibitor

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a87475d0ea5c1621ac79cc4a9f6e09d4Test
https://pubmed.ncbi.nlm.nih.gov/33058504Test

9

Current Clinical Progress of PD-1/PD-L1 Immunotherapy and Potential Combination Treatment in Non–Small Cell Lung Cancer

المؤلفون: Ao Sun, Elaine Lai-Han Leung, Pei-Yu Yan, Ze-Bo Jiang, Ju-Min Huang, Jia-Xin Li, Run-Ze Li

المصدر: Integrative Cancer Therapies, Vol 18 (2019)
Integrative Cancer Therapies

مصطلحات موضوعية: 0301 basic medicine, Oncology, medicine.medical_specialty, Durvalumab, Lung Neoplasms, medicine.medical_treatment, Population, Programmed Cell Death 1 Receptor, review, Antineoplastic Agents, Pembrolizumab, Review Article, lcsh:RC254-282, B7-H1 Antigen, Targeted therapy, Avelumab, 03 medical and health sciences, 0302 clinical medicine, non–small cell lung cancer, combinational therapy, Atezolizumab, Internal medicine, Carcinoma, Non-Small-Cell Lung, medicine, Humans, Medicine, Chinese Traditional, Lung cancer, education, education.field_of_study, business.industry, PD-1/PD-L1 inhibitor, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, 030104 developmental biology, Complementary and alternative medicine, 030220 oncology & carcinogenesis, biomarker, Chinese herbal medicine, Immunotherapy, Nivolumab, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e87e18cf82928788a90008cb407d028cTest
https://doaj.org/article/622118b438a94a22b285817aece42af3Test

10

Comparative Impact of PD-1 and PD-L1 Inhibitors on Advanced Esophageal or Gastric/Gastroesophageal Junction Cancer Treatment: A Systematic Review and Meta-Analysis

المؤلفون: Eun Young Kim, SuA Oh, Heeyoung Lee

المصدر: Journal of Clinical Medicine, Vol 10, Iss 3612, p 3612 (2021)
Journal of Clinical Medicine

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::097539d27cbce5525244ac8529a0733fTest
https://doi.org/10.3390/jcm10163612Test

تنقيح النتائج